Published: Apr 07, 2021
- Program Powered by Applied DNA’s Mutation-targeted qPCR Assays and NGS Platform -
- Program Data Potentially Relevant to COVID-19 Vaccine and Therapeutics Developers, Precision Medicine -
STONY BROOK & NEW HYDE PARK, N.Y. (BUSINESS WIRE) Applied DNA Sciences, Inc.. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and Northwell Health (Northwell) today announced their entry into a
pro bono Material Transfer Agreement (MTA) that establishes a real-time surveillance program for the tracking and identification of SARS-CoV-2 mutations and variants of concern (VoCs) in Northwell’s COVID-positive specimens (the “Program”). Under the Program, de-identified positive COVID-19 specimens supplied by Northwell are being screened for SARS-CoV-2 mutations found in currently known VoCs using Applied DNA’s Linea